Intelligent Bio Solutions Secures 8 New Customers with a Combined Workforce of Over 10,000 Employees Two Months into Product Launch in Australia
01 Agosto 2023 - 9:30AM
Intelligent Bio Solutions Inc. ("Intelligent Bio Solutions," "INBS"
or the "Company") (Nasdaq: INBS), a medical technology company
delivering intelligent, rapid, non-invasive testing solutions,
today announced it has secured 8 new customers across various
locations throughout Australia, which collectively employ over
10,000 individuals, within just two months of launching its
Intelligent Fingerprinting Drug Screening System in Australia.
Since the Company’s entry into the Australian
market with its Intelligent Fingerprinting Drug Screening System,
the dedicated efforts of the sales force have resulted in the
addition of 8 new customers across the Mining, Aviation,
Construction, Manufacturing, and Agriculture industries. The
thriving market expansion in Australia highlights the growing
demand for alternative screening solutions across multiple sectors,
particularly those in which maintaining workplace safety is
critical.
"Our rapidly expanding customer footprint across
the region is a testament to our innovative technology and the
quality and value of our drug screening solution," said Harry
Simeonidis, President and Chief Executive Officer of Intelligent
Bio Solutions. "We remain focused on advancing this growth and
delivering a convenient and dignified alternative that continues to
meet the screening needs of businesses across Australia."
About Intelligent Bio Solutions
Inc.
Intelligent Bio Solutions Inc. (the "Company")
(Nasdaq: INBS) is a medical technology company delivering
intelligent, rapid, non-invasive testing solutions. The Company
believes that its Intelligent Fingerprinting Drug Screening System
will revolutionize portable testing through fingerprint sweat
analysis, which has the potential for broader applications in
additional fields. This hygienic, and cost-effective system is
designed to screen for recent use of drugs commonly found in the
workplace, including opioids, cocaine, methamphetamine, and
cannabis. With sample collection in seconds and results in under
ten minutes, this technology would be a valuable tool for employers
in safety-critical industries. Additionally, the Company's
biosensor platform has the potential to test for up to 130
indications, ranging from glucose to immunological conditions and
communicable diseases. The Company’s current customer segments
include construction, manufacturing and engineering, transport and
logistics firms, drug treatment organizations, and coroners.
For more information, visit:
http://www.ibs.inc/
Forward-Looking Statements:
Some of the statements in this release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, Section 21E of the Securities Exchange Act
of 1934 and the Private Securities Litigation Reform Act of 1995,
which involve risks and uncertainties. Forward-looking statements
in this press release include, without limitation, Intelligent Bio
Solutions Inc.’s ability to develop and commercialize its
diagnostic tests, realize commercial benefit from its partnerships
and collaborations, and secure regulatory approvals, among others.
Although Intelligent Bio Solutions Inc. believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Intelligent Bio Solutions
Inc. has attempted to identify forward-looking statements by
terminology, including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, included in Intelligent
Bio Solutions’ public filings filed with the Securities and
Exchange Commission. Any forward-looking statements contained in
this release speak only as of its date. Intelligent Bio Solutions
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
Company Contact: Intelligent
Bio Solutions Inc. info@ibs.inc
Media Contact: Cheryl Billson
Comma Communications cheryl.billson@commacomms.com
Investor Contact:Valter
PintoKCSA Strategic CommunicationsINBS@kcsa.com
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Intelligent Bio Solutions (NASDAQ:INBS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024